Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Keryx Depletes Kidney Drug Supply, Production to Blame

A production issue has led Keryx to withdraw financial guidance for 2016 as they seek a new manufacturer to take on Auryxia.

Keryx / Image: Keryx
Keryx / Image: Keryx

An August 2nd FiercePharma article reported that Keryx Biopharmaceuticals has run out the only drug they make. Keryx says their production contractor for Auryxia encountered complications converting the active pharmaceutical ingredient into a finished product. The glitch has left patients without the drug until at least October. News of the company withdrawing its guidance for the year caused the stock to plummet 35.87%.

“Although we are withdrawing our financial guidance for 2016, we believe we are well positioned financially to manage through this interruption in supply of Auryxia,” said CFO Scott Holmes. The company is in the process of vetting out a second manufacturer to handle production, but the FDA won’t make a decision until mid-November. In the meantime, hyperphosphatemia patients on Keryx will have to opt for the much larger competitor, Sanofi’s Renvela.

List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?